alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 516.20 Content and format of a request for MUMS-drug designation. ( a ) A sponsor that submits a request for designation of a new animal drug intended for a minor use or minor species must submit each request in the form and containing the information required in paragraph (b) of this section. While a request for designation may involve multiple intended uses, each request for designation must constitute a separate submission. A sponsor may request MUMS-drug designation of a previously unapproved drug, or a new intended use or dosage form for an already conditionally approved or approved drug. Only one sponsor may receive MUMS-drug designation of the same drug, in the same dosage form, for the same intended use.
( b ) A sponsor must submit two copies of a completed, dated, and signed request for designation that contains the following information: ( 1 ) A request for designation of a new animal drug for a minor use or use in a minor species, which must be specific.
( 2 ) The name and address of the sponsor; the name of the sponsor's primary contact person and/or permanent-resident U.S. agent including title, address, and telephone number; the established name (and proprietary name, if any) of the active pharmaceutical ingredient of the drug; and the name and address of the source of the active pharmaceutical ingredient of the drug.
( 3 ) A description of the proposed intended use for which the drug is being or will be investigated.
( 4 ) A description of the drug and dosage form.
( 5 ) A discussion of the scientific rationale for the intended use of the drug; specific reference, including date(s) of submission, to all data from nonclinical laboratory studies, clinical investigations, copies of pertinent unpublished and published papers, and other relevant data that are available to the sponsor, whether positive, negative, or inconclusive.
( 6 ) A specific description of the product development plan for the drug, its dosage form, and its intended use.
( 7 ) If the drug is intended for a minor use in a major species, documentation in accordance with § 516.21, with appended authoritative references, to demonstrate that such use is a minor use.
( 8 ) A statement that the sponsor submitting the request is the real party in interest of the development and the intended or actual production and sales of the product.
( 9 ) A statement that the sponsor acknowledges that, upon granting a request for MUMS designation, FDA will make information regarding the designation publicly available as specified in § 516.28.
[72 FR 41017, July 26, 2007, as amended at 75 FR 69588, Nov. 15, 2010; 77 FR 18685, Mar. 28, 2012]
|   | 1. | I have reviewed this Quarterly Report on Form 10-Q of Crimson Exploration Inc.; |
|--------|----|---------------------------------------------------------------------------------|

|   | 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  | May 11, 2010              |   |
|-------------|---------------------------|--------|
|        | /s/ E. Joseph Grady       |   |
| Name:       | E. Joseph Grady           |   |
| Title:      | Senior Vice President and |   |
|        | Chief Financial Officer   |   |

----
<PAGE>   1
                                                                     EXHIBIT 5.1

                                PERKINS COIE LLP
          1201 THIRD AVENUE, 40TH FLOOR, SEATTLE, WASHINGTON 98101-3099
               TELEPHONE: (206) 583-8888 FACSIMILE: (206) 583-8500



                                 March 25, 1998



Frontier Financial Corporation
332 S.W. Everett Mall Way
P.O. Box 2215
Everett, WA  98203

         Re: Registration Statement on Form S-8 of Shares of Common Stock, No
             Par Value Per Share, of Frontier Financial Corporation

Ladies and Gentlemen:

         We have acted as counsel to you in connection with the preparation of a
Registration Statement on Form S-8 (the "Registration Statement") under the
Securities Act of 1933, as amended (the "Act"), which you are filing with the
Securities and Exchange Commission with respect to 526,183 shares of Common
Stock, no par value per share (the "Shares"), which may be issued pursuant to
the Frontier Financial Corporation Incentive Stock Option Plan (the "Plan"). We
have examined the Registration Statement and such documents and records of the
Company and other documents as we have deemed necessary for the purpose of this
opinion. In giving this opinion, we are assuming the authenticity of all
instruments presented to us as originals, the conformity with originals of all
instruments presented to us as copies and the genuineness of all signatures.

        Based upon and subject to the foregoing, we are of the opinion that upon
(a) the action of the shareholders of Frontier Financial Corporation approving
an increase in the number of shares that may be issued under the Plan and (b)
the due execution by the Company and the registration by its registrar of such
Shares, issuance thereof by the Company in accordance with the terms of the
Plan, and the receipt of consideration therefor in accordance with the terms of
the Plan, such Shares will be duly authorized, validly issued, fully paid and
nonassessable.

         We hereby consent to the filing of this opinion as Exhibit 5.1 to the
Registration Statement. In giving such consent, we do not admit that we are in
the category of persons whose consent is required under Section 7 of the Act.

                                                     Very truly yours,


                                                     PERKINS COIE LLP
<PAGE>   1


                                                                    EXHIBIT 23.2


                CONSENT OF NETHERLAND, SEWELL & ASSOCIATES, INC.


To the Board of Directors of Forcenergy Inc:

We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (File Nos. 333-30524 and 333-32720) of Forcenergy Inc of
our reports dated February 28, 2000, March 5, 1999 and March 4, 1998, of the
estimates of net proved oil and natural gas reserves of Forcenergy Inc, and
their present values, as of January 1, 2000, 1999 and 1998, included in this
Annual Report on Form 10-K for the year ended December 31, 1999.



                                         NETHERLAND, SEWELL & ASSOCIATES, INC.



                                         By: /s/ Danny D. Simmons
                                            --------------------------------
                                             Danny D. Simmons
                                             Senior Vice President
                                             Houston, Texas
                                             March 30, 2000
Toll Manufacturing of an

alkanolamine acid anhydride

reaction product
Missouri Court of Appeals

Southern District 

MAY 22, 2015 

THE FOLLOWING CASES WERE AFFIRMED IN ACCORDANCE WITH RULE 84.16(b). 

1. SD33418 DON STEWART, et al., Respondent 

 vs. 

 SPOKANE R-VII SCHOOL DISTRICT, Appellant
<PAGE>   1
               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

   
We consent to reference to our firm under the caption "Experts" in Amendment No.
2 to the Registration Statement (Form S-3) and related Prospectus of InControl,
Inc. for the registration of 400,000 shares of its common stock and to the
incorporation by reference therein of our report dated January 29, 1998, with
respect to the consolidated financial statements of InControl, Inc. included in
its Annual Report (Form 10-K/A) for the year ended December 31, 1997, filed with
the Securities and Exchange Commission.
    

  
                                                           /s/ ERNST & YOUNG LLP


Seattle, Washington
July 19, 1998
Editorial Note on Part 170
Editorial Note: Nomenclature changes to part 170 appear at 66 FR 56035, Nov. 6, 2001, and 69 FR 13717, Mar. 24, 2004.

§ 170.270 Procedures that apply when the intended conditions of use of a notified substance include use in a product or products subject to regulation by the Food Safety and Inspection Service (FSIS) of the United States Department of Agriculture. If the intended conditions of use of the notified substance include use in a product or products subject to regulation by FSIS under statutes that it administers: ( a ) When applicable, you must include in your GRAS notice a statement as to whether you: ( 1 ) Authorize us to send any trade secrets to FSIS; or
( 2 ) Ask us to exclude any trade secrets from the copy of the GRAS notice that we will send to FSIS.
( b ) ( 1 ) We will forward a copy of a GRAS notice or relevant portions thereof to FSIS;
( 2 ) We will exclude any trade secrets unless you have authorized us to do so in accordance with paragraph (a)(1) of this section; and
( c ) We will ask FSIS to advise whether the intended conditions of use comply with applicable statutes and regulations, or, if not, whether the use of the substance would be permitted in products under FSIS' jurisdiction under specified conditions or restrictions.
( d ) As appropriate, we will inform you of the advice we receive from FSIS in the letter we send you in accordance with § 170.265(b)(1).
Exhibit






Exhibit 10.3


AMENDMENT TO THE
VIACOM BONUS DEFERRAL PLAN 
FOR DESIGNATED SENIOR EXECUTIVES


1.Effective as of March 13, 2017, Section 2.5 of the Plan is amended to read in its entirety as follows:


2.5    Committee.  The term "Committee" means the Retirement Committee appointed hereunder.  The Committee may act on its own behalf or through the actions of a duly authorized delegate or delegates.


2.Effective as of March 13, 2017, Section 9.1 of the Plan is amended to read in its entirety as follows:


9.1    Committee.  This Plan will be administered by the Committee as an unfunded plan that is not intended to meet the qualification requirements of Section 401(a) of the Code.  The Committee shall consist of the Executive Vice President/Chief Administrative Officer, the Senior Vice President/Head of Compensation & Benefits and Deputy General Tax Counsel, and the Senior Vice President/Compensation and Benefits; provided, however, that the Executive Vice President/Chief Administrative Officer may add members and may remove members.  If there is no employee holding such title, the person acting in that capacity or holding a successor title, as appropriate, shall serve in that position on the Committee (but if such person is already a member, he/she shall have only one vote).
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                          35,006
<SECURITIES>                                         0
<RECEIVABLES>                                2,322,372
<ALLOWANCES>                                    10,000
<INVENTORY>                                  2,447,600
<CURRENT-ASSETS>                             5,810,746
<PP&E>                                      94,881,225
<DEPRECIATION>                               6,752,381
<TOTAL-ASSETS>                              95,038,547
<CURRENT-LIABILITIES>                        5,797,094
<BONDS>                                      7,655,839
<PREFERRED-MANDATORY>                       15,932,955
<PREFERRED>                                          0
<COMMON>                                        38,430
<OTHER-SE>                                  62,093,616
<TOTAL-LIABILITY-AND-EQUITY>                95,038,547
<SALES>                                      7,993,854<F1>
<TOTAL-REVENUES>                             7,993,854<F1>
<CGS>                                        6,371,882
<TOTAL-COSTS>                                8,793,024
<OTHER-EXPENSES>                              (18,311)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (780,859)
<INCOME-TAX>                                 (292,822)
<INCOME-CONTINUING>                          (488,037)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (488,037)
<EPS-PRIMARY>                                   (0.06)
<EPS-DILUTED>                                   (0.06)
<FN>
<F1>SALES AND TOTAL REVENUES ARE NET OF FEDERAL AND STATE EXCISE TAXES
</FN>
        

</TABLE>
<PAGE>   1
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                       -----------------------------------


                                    FORM 8-K

                                 CURRENT REPORT


     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934




                                OCTOBER 30, 1998
--------------------------------------------------------------------------------
                                (Date of Report)



                             SPACELABS MEDICAL, INC.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


    DELAWARE                      0-20083                      91-1558809
----------------           ----------------------         -------------------
(State or other            Commission File Number           (I.R.S. Employer
jurisdiction of                                           Identification No.)
incorporation or
 organization)


        15220 N.E. 40TH STREET
         REDMOND, WASHINGTON                                       98073
----------------------------------------                         ----------
(Address of principal executive offices)                         (Zip Code)
               


                                 (425) 882-3700
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)


<PAGE>   2
ITEM 8.  CHANGE IN FISCAL YEAR

     On October 30, 1998, the Company's Board of Directors approved a change in
the Company's fiscal year end from a 52-53 week year ending the last Friday in
December to a December 31 year end. The transition period from December 26, 1998
to December 31, 1998 will be included in the Company's Annual Report on Form
10-K for the year ending December 31, 1998.


<PAGE>   3
SIGNATURES

Pursuant to the requirements of Section 13 or Section 15(d) the Securities and
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.



       SPACELABS MEDICAL, INC.
       -----------------------------------
           (Registrant)



Dated:   November  9, 1998                By  /s/  Carl A. Lombardi
                                              ----------------------------------
                                              Carl A. Lombardi
                                              Chairman of the Board
<PAGE>

Exhibit 23

                        CONSENT OF INDEPENDENT AUDITORS'

The Board of Directors
The Guarantee Life Companies Inc:

We consent to incorporation by reference in Registration Statement Nos. 333-
17863 and 333-22461 on Form S-8 of The Guarantee Life Companies Inc. of our
reports dated February 14, 1997 relating to the consolidated balance sheets of
The Guarantee Life Companies Inc. and subsidiaries (Guarantee Life) as of
December 31, 1996 and December 31, 1995, and the related consolidated statements
of income, shareholders' equity and cash flows and related schedules for each of
the years in the three-year period ended December 31, 1996, which reports are
included or incorporated by reference in the December 31, 1996 Annual Report on
Form 10-K of The Guarantee Life Companies Inc.

Our report refers to Guarantee Life's adoption of Statement of Financial
Accounting Standards No. 115, Accounting for Certain Investment in Debt and
                              ---------------------------------------------
Equity Securities, in 1994.
-----------------


KPMG Peat Marwick LLP
Omaha, Nebraska
March 27, 1997
May 22 , 2018



### JUDGMENT 

## The Fourteenth Court of Appeals

IN THE INTEREST OF W .A.B., III, A CHILD

NO. 14

- 18

- 00181

- CV

________________________________ Today the Court heard its own motion to dismiss the appeal from the judgment signed by the court below on November 7, 2017. Having considered the motion and found it meritorious, we order the appeal DISMISSED

. We further order that all costs incurred by reason of this appeal be paid by appellant. We further order this decision certified below for observance.
#### BARTHEL *v.*CRIPPEN.

Appeal and Error — Motion to Remand — Decision—Postponement.

The decision of a motion to remand a chancery case to the circuit court for the introduction of testimony discovered since the appeal was perfected is reserved till the hearing of the appeal.

Bill by Otto F. Barthel against George F. Crippen and Lewis Crippen for the specific performance of a contract. From a decree for complainant, defendants appeal: On motion to remand the record for a rehearing.

Submitted October 6, 1908.

(Calendar No. 22,361.)

Motion denied November *2,*1908.

*Lee N. Brown,*for the motion.

*Henry O. L. Forler,*contra.

Per Curiam.

This is a motion on behalf of defendants and appellants for the remanding of the record in the above-entitled cause to the circuit court for the county of Wayne, in chancery, for the introduction of further testimony on the part of defendants, alleged to be material and necessary to a just determination of the issues involved and to have been discovered since the appeal to this court was perfected.

In accordance with the practice approved by this court in *Adams*v. *Field, 25*Mich. 16, the question of a rehearing will be reserved till the hearing of the appeal.
§ 21.72 Individual consent to disclosure of records to other persons. ( a ) Individuals may consent to disclosure of records about themselves to other persons in several ways, for example: ( 1 ) An individual may give consent at the time that the information is collected for disclosure for specific purposes or to specific persons.
( 2 ) An individual may give consent for disclosure of his records to a specific person.
( 3 ) An individual may request the Food and Drug Administration to transcribe a specific record for submission to another person.
( b ) In each case the consent shall be in writing and shall specify the individual, organizational unit, or class of individuals or organizational units to whom the record may be disclosed, which record may be disclosed, and, if applicable, for what time period. A blanket consent to release all of an individual's records to unspecified individuals or organizational units will not be honored. Verification of the identity of the individual and, where applicable, of the person to whom the record is to be disclosed shall be made in accordance with § 21.44. Consent documents shall be retained for a period of at least 2 years. If such documents are used as a means of accounting for the disclosure, they shall be retained as provided in § 21.71(e)(2).